Physician profile
Maxwell Tran
NPI 1922595057
$1,241.42
in general payments reported to CMS, 2019-2025
28 companies · $973 in 2025
The $973 reported for 2025 was more than what 83% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $269 · 2025: $973.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,241.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $169.20 | 2024-2025 | |
| Janssen Biotech, INC. | $124.14 | 2024-2025 | Talvey, Darzalex, Erleada |
| Alexion Pharmaceuticals, INC. | $92.06 | 2025 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $75.14 | 2025 | Calquence |
| Glaxosmithkline, LLC. | $69.06 | 2024-2025 | Zejula |
| Exelixis INC. | $62.38 | 2024-2025 | Cabometyx |
| Sumitomo Pharma America, INC. | $59.21 | 2024-2025 | Orgovyx |
| Merck Sharp & Dohme LLC | $52.47 | 2024-2025 | Keytruda, Lynparza |
| Daiichi Sankyo INC. | $47.97 | 2024-2025 | Enhertu |
| Aveo Pharmaceuticals, INC. | $39.53 | 2025 | |
| Genentech USA, INC. | $37.50 | 2025 | Polivy, Tecentriq |
| Pharmacosmos Therapeutics INC. | $33.84 | 2024-2025 | Monoferric |
| Dendreon Pharmaceuticals LLC | $33.69 | 2025 | Provenge |
| Pfizer INC. | $32.08 | 2025 | |
| Stemline Therapeutics INC. | $31.76 | 2024-2025 | Orserdu |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $29.35 | 2025 | |
| Pharmaessentia USA Corporation | $27.88 | 2025 | Besremi |
| Incyte Corporation | $25.96 | 2025 | Jakafi |
| Regeneron Healthcare Solutions, INC. | $25.04 | 2025 | Lynozyfic |
| Servier Pharmaceuticals LLC | $24.46 | 2025 | |
| Beone Medicines USA, INC. | $23.13 | 2025 | Brukinsa |
| Celgene Corporation | $22.82 | 2025 | Reblozyl |
| Geron Corporation | $20.16 | 2025 | Rytelo |
| Eisai INC. | $18.88 | 2025 | |
| Karyopharm Therapeutics INC. | $18.55 | 2025 | Xpovio |
| E.R. Squibb & Sons, L.L.C. | $15.74 | 2024 | Eliquis |
| Iovance Biotherapeutics, INC. | $15.38 | 2025 | Amtagvi |
| Taiho Oncology, INC. | $14.04 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maxwell Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.